The secondary objectives of this study are to assess:~A. The maintenance of medium-term effectiveness of ketamine on the resolution of suicidal ideation~B. The evolution of the full spectrum of suicidality under ketamine compared to placebo~C. The evolution of psychic and physical pain scores under ketamine compared to placebo~D. The evolution of Beck Hopelessness score which is a predictor of long-term suicide risk, under ketamine compared to placebo~E. The early antidepressant efficacy of ketamine in depressed, uni- or bipolar patients~F. The somatic and psychological tolerance of ketamine~G. An overall improvement in the clinical condition of the patient by the practitioner~H. Creation of a biological collection for future ancillary studies dedicated to genetic analysis (microRNA and mRNA).~I. The efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS self-report questionnaire, in patients hospitalized for suicide risk.
The primary objective of this study is to assess the efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS hetero questionnaire, in patients hospitalized for suicide risk.